Trial Profile
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Diphtheria; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Wyeth
- 11 Jun 2009 Results presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), according to a Wyeth media release.
- 12 Aug 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
- 17 Nov 2006 Status change